U.S. Markets closed

Ligand Pharmaceuticals Inc (LGND) CEO John L Higgins Bought $108,200 of Shares

- By insider

CEO of Ligand Pharmaceuticals Inc (LGND) John L Higgins bought 1,000 shares of LGND on 05/31/2019 at an average price of $108.2 a share. The total cost of this purchase was $108,200.

Ligand Pharmaceuticals Inc is a biopharmaceutical company. Its business model is based upon the concept of acquiring royalty revenue generating assets and coupling them with a lean corporate cost structure. Ligand Pharmaceuticals Inc has a market cap of $2.1 billion; its shares were traded at around $107.38 with a P/E ratio of 3.08 and P/S ratio of 10.51. Ligand Pharmaceuticals Inc had annual average EBITDA growth of 57.40% over the past five years.


CEO Recent Trades:

  • CEO John L Higgins bought 1,000 shares of LGND stock on 05/31/2019 at the average price of $108.2. The price of the stock has decreased by 0.76% since.
  • CEO John L Higgins bought 2,500 shares of LGND stock on 05/14/2019 at the average price of $113.5. The price of the stock has decreased by 5.39% since.

Directors and Officers Recent Trades:

  • Director Jason Aryeh bought 1,000 shares of LGND stock on 05/31/2019 at the average price of $109.51. The price of the stock has decreased by 1.95% since.
  • Director Jason Aryeh bought 250 shares of LGND stock on 05/20/2019 at the average price of $112.01. The price of the stock has decreased by 4.13% since.
  • Director Jason Aryeh bought 250 shares of LGND stock on 05/14/2019 at the average price of $112.51. The price of the stock has decreased by 4.56% since.
  • Director John W Kozarich sold 2,500 shares of LGND stock on 05/14/2019 at the average price of $112.92. The price of the stock has decreased by 4.91% since.

For the complete insider trading history of LGND, click here

.This article first appeared on GuruFocus.